Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 4Withdrawn 2Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 1

Conditions

Squamous Cell Carcinoma of the Lung 1Skin Neoplasms 1Melanoma 1

Interventions

Cyclophosphamide 390Carboplatin 343Gemcitabine 331pembrolizumab 330Cisplatin 327Paclitaxel 295Radiotherapy 292Docetaxel 286Bevacizumab 249Rituximab 233Capecitabine 222Nivolumab 220Dexamethasone 205Fluorouracil 189fludarabine 178Oxaliplatin 177Pemetrexed 153Doxorubicin 152Irinotecan 147Etoposide 144Leucovorin 143Cytarabine 134fludarabine phosphate 129Bortezomib 129Cetuximab 127Lenalidomide 125Filgrastim 120Erlotinib Hydrochloride 119Temozolomide 111Ipilimumab 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Interventional × glembatumumab vedotin × Clear all
NCT02302339 2019-09-06

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Celldex Therapeutics

Phase 2 Terminated
132 enrolled 16 charts
Dermatologic

Melanoma, Skin Neoplasms

NCT02713828 2019-07-16

PrE0504

PrECOG, LLC.

Phase 1/2 Terminated
13 enrolled 12 charts

Squamous Cell Carcinoma of the Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡